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Abstract
Exposure to arsenic (As) is a global health concern, according to the World
Health Organization and Agency for Toxic Substances and Disease Registry. Prolonged
exposure to this naturally occurring chemical has been linked to hyperkeratosis, type II
diabetes, developmental abnormalities, and cancer. Some of the adverse health effects of
As may be linked to its ability to alter cellular signal transduction. Recently, published
work from the Gosse laboratory has shown that inorganic arsenite inhibits the signaling
cascade leading to mast cell degranulation, a vital immune function, through an as-yet
unknown mechanism.
Further work in the Gosse lab has suggested that arsenic’s effect occurs early in
the degranulation signaling pathway, between receptor aggregation and calcium influx.
Alternate FcεRI cross-linking methods produced similar As inhibition patterns,
suggesting an As effect downstream of receptor aggregation. Calcium ionophore and
compound 48/80-mediated degranulation responses were not inhibited by As-- evidence
that arsenic’s effect occurs upstream of calcium influx as well. This thesis will
concentrate on testing the hypothesis that As disrupts antigen-stimulated tyrosine
phosphorylation of Syk kinase, a signaling molecule functioning between receptor
aggregation and calcium influx in mast cells. Using a piceatannol-arsenic combination
assay it was found that Syk and piceatannol, a competitive inhibitor of Syk, cause an
additive inhibitory effect on degranulation. Preliminary Phospho-Syk ELISA data
provides evidence that arsenic may be interfering with the phosphorylation of Syk, a vital
process during the development of hypersensitivity. Taken together, these data provide
insight into possible mechanisms of toxicity of arsenic as well as a possible drug target in
the treatment and prevention of asthma and allergy.
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1. Introduction
1.1. Arsenic
Arsenic (As) is a metalloid commonly found in the Earth’s crust at an average
concentration of 2mg/ kg and as high as 100mg/kg as part of copper or lead ores, and
within minerals in the soil [1]. Elemental arsenic, insoluble in water, is most commonly
found in the environment combined with oxygen, sulfur, and chlorine, and is known as
inorganic arsenic in this form. The most common arsenic-containing mineral in the soil is
arsenopyritein (FeAsS), but arsenic is known to be associated with more than 200
different other minerals, especially those containing sulfide [1, 2, 3]. In the environment,
inorganic arsenic can assume two valence states described as arsenite (As(III)) and
arsenate (As (V)) [4]. Under reducing conditions the trivalent form is most prevalent,
while in highly oxygenated environments (oxidizing conditions), the pentavalent form
predominates [1]. Its trivalent form, arsenite, has been shown to be the more toxic of the
two even in its monomethylated state [5]. The methods for possible toxicity will be
discussed in later sections.
Sources of arsenic are varied and plentiful. Humans can come in contact with
arsenic through the consumption of contaminated water and food, inhalation of industrial
emissions from copper or lead smelting, as well as routine occupational exposure. For the
general population, the most relevant exposure to arsenic is through the consumption of
contaminated drinking water from wells located near mineral deposits [1, 6]. The levels
of arsenic in drinking water vary by region but are estimated to range between 1 and 1000
2

ppb (µg/L). However, in areas such as West Bengal, India, Bangladesh, North Mexico,
Chile and Argentina millions of people are affected by levels of arsenic in their drinking
water ranging from 50 to 3000 ppb (µg/L)[1, 6]. Areas near sulfide mineralization and
geochemical sites near Taiwan reported groundwater level of arsenic as high as 1 ppm
(mg/L) [7].
Contaminated drinking water is the major source of arsenic exposure in humans,
but consumption of arsenic-bearing foods like shellfish, cereals, and vegetables can also
be a substantial source. A study of inorganic arsenic in the typical Hong Kong diet found
levels of arsenic as high as 74 µg/kg (this is elemental arsenic per wet body weight;
comparable to ppb) in water spinach, and 58 µg/kg (58 ppb) in oysters [9]. The highest
arsenic-exposure contributing products were cereals with 53.5% contribution to the diet
of the average Hong Kong citizen, with brown (unpolished) rice having the highest
concentration of arsenic at 43 µg/kg (43 ppb). The study concluded that the high levels of
arsenic in these foods are likely due to their aquatic growing conditions [9]. These Hong
Kong study is one only of many similar studies attempting to elucidate the human dietary
exposure to arsenic. Closer to home, the Consumer Reports magazine did a study of their
own. Similar to the Hong Kong study, it was found that cereals were the largest
contributor of arsenic with uncooked rice topping the charts at levels as high 900 ppb
(900 µg/mL) [10]. Levels of arsenic in food this high are cause for concern given the
major health problems that are linked to chronic exposure of arsenic.
1.2. Arsenic & Human Health
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Due to its high prevalence in the environment, there has been a lot of attention on
how exposure to arsenic affects the human body. Acute arsenic exposure (acute
poisoning) can occur when the digestion of large amounts (>5mg) of arsenic containing
products, such as insecticides, occurs. One-time doses of about 5mg of arsenic are
described as causing minor complications such as vomiting and diarrhea; however, doses
ranging from 100mg to 300mg can cause skin rashes, cardiomyopathy, seizures, renal
failure, pulmonary edema and eventually death [11]. Acute poisoning of arsenic is rare
and often accidental; however, chronic consumption of small doses (for example, 50
µg/L (or 50 ppb) in drinking water) of arsenic is just as dangerous and a more prevalent
issue worldwide. Long term exposure to low levels of arsenic has been linked to health
issues ranging from hyperpigmentation and keratosis to an increased risk of
cardiovascular disease, respiratory disease, diabetes mellitus, and cognitive impairment
[1, 11]. Chronic exposure to arsenic, however, has been most clearly linked with cancer
development in nearly all organ systems of the body [1, 11, 12]. The U.S Environmental
Protection Agency released a statement claiming that a lifetime exposure to arsenic as
low as 1 ppb has been linked to having a significantly higher risk of developing skin
cancer [6]. It is clear, then, that due to the high prevalence of arsenic in the environment
and the large number of health concerns linked to arsenic exposure, the mechanism of
toxicity warrants heavy scientific concern.
1.3. Arsenic & Cell Signaling
Some of the adverse health effects of As may be linked to its ability to alter
cellular signal transduction [13, 14]. Arsenic has been linked with the formation of
harmful reactive oxygen species (ROS) and the disruption of tyrosine phosphorylation in
4

many cell lines and model organisms [4, 13, 14, 15, 16, 17]. Arsenic-induced ROS
formation has been shown to cause DNA damage and protein alteration. In a study using
AL human-hamster hybrid cells a significant increase in ROS production was observed
within the first 5 min of exposure [20]. Furthermore, a decrease in nonprotein sulfhydryls
caused a 5-fold increase in intragenic and multilocus deletion mutations in the DNA of
these cells providing strong evidence for possible mechanistic routes of cancer
development induced by arsenic [20]. Additionally, it has been well documented that As
can have adverse effects on phosphorylation pathways [4, 13, 16, 17, 18]. For example,
As has been linked with a significant decrease in cytokine production (IL-2) of splenic
mononuclear cells in male mice [15]. This disruption of T-cell activation was concluded
to be linked with an increase in the levels of phosphorylation of the early protein tyrosine
phosphorylation cascade proteins that included Lck and Fyn kinases [15].Whether this
effect is through the substitution of phosphate groups by the isostructural compound
arsenate [13, 16, 18], the ability of arsenite to interact with sulfhydryl groups [13], or
arsenite’s ability to form reactive oxygen species that inactivate kinases or phosphatases
[13,16], or some other mechanism, it is evident that the next logical step would be to
focus our research on the early phosphorylation events of cell signaling.
1.4. Mast Cells & RBL-2H3 Cell Line
The mast cell, as a key player in parasite defense and the allergy response, is an
important cell line to keep in mind through the evaluation of arsenic exposure and its
effects. Mast cells, as leukocytes, play a major role in defense against pathogens and are
derived from haematopoietic progenitor cells [8, 19, 21]. Prior to maturation within the
mucosal and connective tissues, mast cells circulate through the vascular system as
5

progenitors following a model of development similar to that of a macrophage [8, 19]. A
specific progenitor has only been successfully identified in fetal blood and they are
described as expressing the cluster of differentiation (CD) molecules, CD34, CD117 (ckit), and CD13 in humans and Thy-1loc-kithi cell in mouse [8, 22]. However, the cell
progenitors identified in this study lacked the expression of the FcεRI receptor that is
often associated with parasite defense, and FcεRI expression was only induced via
experimental methods in vivo and in vitro, thus an appropriate mast cell progenitor still
has yet to be identified [8].
Mast cells contribute to the defense against parasites via the degranulation
process, in which compounds meant to fight off parasitic infection are released from the
cells’ intracellular granules.

Activation of this degranulation pathway is triggered by

antigen, or allergen, from a foreign organism, which crosslinks IgE-bound FcεRI
receptors, thus triggering an internal signaling pathway eventually leading to the release
of pro-inflammatory meditators through degranulation [23, 24, 25, 26, 27]. Antigen
stimulation sets in motion a cascade of tyrosine phosphorylation events that notably
include the kinases Lyn and Syk [23, 24, 25, 28, 29, 30], among others. The
phosphorylation of the receptor and the kinases leads to calcium influx and the
mobilization and fusion of mediator-filled granules with the plasma membrane [23, 24,
25, 28, 29]. Within these aformentioned pre-formed granules we find the mediators
histamine, a well described player in the allergic response, tryptase and chymases
(proteases), tumor necrosis factor-alpha and many other cytokines that are found to be
vital in the non-specific branch of the immune system [19, 25, 23]. More detail will be
included in the “degranulation pathway” section.
6

The degranulation pathway has been extensively studied through the use of Rat
Basophilic Leukemia (RBL) cells as model for basophils, due to their reliable release of
histamine through the stimulation of FcεRI receptors [31] and their functional similarity
to primary human basophils and rodent mast cells [32, 33]. In the literature, the RBL-2H3
cell line has been described as sharing functional and phenotypic similarities with
basophils and mast cells [34]. The 2H3 cell line has been shown to respond in a similar
fashion to the calcium ionophore A23187, as do basophils and mast cells [34]. Much like
basophils and mast cells, RBL-2H3 release β-hexosaminidase, an exoglycosidase, from
the granules in parallel with histamine and the other mediators, which lends itself as way
to quantify degranulation [34, 35]. The presence of Toll Like Receptor 4 (TLR4) on the
cell surface of both RBL-2H3 and basophils attributes to their similarity; however, unlike
basophils, RBL-2H3 are unable to respond to bacterial lipopolysaccharide membrane
component that has been shown to interact heavily with TLR4 [34]. Furthermore, RBL2H3 has been shown to switch phenotypes depending on the current microenvironment in
which they reside [34] This has been shown by Swieter et al by culturing RBL-2H3 cells
with 3T3 fibroblast that lead to a switch from compound 48/80 insensitive RBLs to
sensitive ones [37].Although RBLs are well accepted as models of basophils and mast
cells, they differ in some phenotypical aspects. For example, RBL cell lines have been
shown to express a different density of FcεRI receptors at the plasma membrane [36].
Given this information we have chosen to use the RBL-2H3 cell line for our investigation
of arsenic’s effects on mast cell degranulation with the reservation that as Passante et al
puts it, “RBL-2H3 cells resemble MMC in some respects, and display their basophilic
lineage in others, their true nature lies somewhere in between [34].”
7

1.5. Mast Cell Degranulation
Activating the degranulation pathway requires the binding of an antigen, a
molecule that elicits an immune response, to the corresponding IgE antibody. This
antibody must first be produced by the workhouse of the immune system, the B cell.
When an antigen enters the body it is challenged by an antigen presenting cells, most
often a dendritic cell, which recognizes the antigen as foreign, integrates it, processes it
and presents it via its Major Histcompatibility Complex molecule [38]. This dendritic cell
migrates to the local lymph-node where it encounters a naïve CD4+ T-helper lymphocyte
(TH cell) that promotes a cytokine exchange and the maturation, and differentiation, of the
naïve TH cell to an antigen-specific TH2 cell [39]. Once activated these antigen-specific
TH2 cell can interact with a cognate B-cell to stimulate the upregulation of CD80/CD86
and CD40 ligands on the TH2 cell. Along with the cytokines secreted by both parties
involved, these changes induce the B cell to proliferate into short lived plasma cells that
immediately produce IgM antibodies. Shortly after, however, these activated B-cells
undergo class switch recombination (stimulated by the CD40 ligation signals and the
cytokines IL-4/IL-13) in which a complex process of rearrangement at the
immunoglobulin heavy chain locus, and an excision and ligation of the DNA, gives rise
to the antigen-specific IgE antibody [38]. Once the class switch recombination is
complete, these antigen-specific B cell continue to proliferate into memory cells and the
IgE producing plasma cells.
The short lived, often less than 3 days, IgE antibodies circulate the tissues to
which they are sequestered and encounter the FcεRI receptor of an un-sensitized mast cell
[40]. Although the FcεRI is constitutively expressed in mast cells [24, 41, 42], the high
8

affinity binding of IgE antibodies upregulates the cell-surface expression of the FcεRI
expression and inhibits the internalization of unbound receptors on the surface [24]. The
high affinity receptor for IgE, or FcεRI, is a membrane-bound tetrameric complex
consisting of the IgE binding α chain, a membrane tetraspanning signal-amplifying β
chain and the disulfide-linked homodimer γ chain that provides the signaling ability to
the receptor [23, 24, 25, 41]. An important fact to note is that murine and human models
differ in their β-chain requirement during receptor expression. Expression of FcεRI in
humans can include the tetrameric form (αβγ2) or the trimeric form (αγ2) and does not
require β chain expression for cell-surface expression like the rodent model does [43].
Rodent FcεRI is strictly found in its tetrameric form and the co-expression of the β-chain
is vital for receptor expression [24, 43]. In both models, the constant (Fc) region of one
free-floating IgE binds to the extracellular portion of a single α chain of a FcεRI receptor
with an affinity of 1 × 1010 M-1 [43, 44].
Upon the 1:1 binding of IgE to FcεRI receptor, the mast cell is said to be
sensitized [45]. A sensitized mast cell can now respond to a specific antigen by binding
the multivalent antigen to multiple receptor-bound IgEs, causing crosslinking and
aggregation of receptors, which initiates the signal transduction pathway leading to
degranulation [23, 24, 45]. Aggregation of the receptors activates the protein tyrosine
kinase (PTKs) Lyn, bound to the β chains of each receptor, which immediately goes on to
phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAMs) of the
receptor neighboring it; this model is known as the transphosphorylation model [46, 47].
There is, however, some dispute as to whether this transphosphorylation model or a lipid
raft based model is at work. The lipid raft model claims that, upon aggregation of the
9

receptors, the aggregated receptors and Lyn (which is tethered to the plasma membrane
via palmitoyl and myristoyl anchors) both favor and are clustered together in cholesteroland saturated fat-rich, detergent resistant microdomains (DRMs). In these small,
specialized regions of the membrane, Lyn and the aggregated receptors are in close
enough proximity to allow Lyn to carry out the phosphorylation of the β and γ chains of
the receptors. In fact, Lyn is more enzymatically active inside DRMs than outside
because of exclusion of certain phosphatases from lipid rafts [48].
Regardless of the model, Lyn has been shown to have a regulatory role during these early
events. Xiao et al used BMMCs with a combination of IgE + anti-IgE, IgE+ low antigen,
and IgE + high antigen treatments and found that the activity of Lyn as well as its
association with FcεRI β subunit was suppressed upon low intensity stimulation, while
high intensity stimulation caused enhanced Lyn activity and higher levels of
phosphorylated FcεRI β subunit and Syk kinase [30].
The ITAMs phosphorylated by Lyn consist of an 18–amino acid motif
(E/DxxYxxLxxxxxxx-YxxL) found on the β and γ chains of each FcεRI receptors; the
ITAMs are crucial to the initiation of the degranulation pathway [43]. Although
activation of Lyn is agreed to be the step following receptor aggregation and eventually
degranulation, it is not the only one. In fact, Lyn-deficient bone-marrow-derived mast
cells showed normal degranulation suggesting a parallel, compensational pathway [49]. It
was later determined that this complementary pathway included the PTK Fyn, known for
maintenance and amplification of calcium (Ca+2) signaling [23, 24], however, in this
study we will concentrate on the primary Lyn pathway.
10

Figure 1: Schematic of the Degranulation Model
Picture was adapted from previous graphics made by Jonathan Pelletier and Rachel Kennedy. Created
in Adobe Illustrator CS5.

The phosphorylation of the β and γ chains of the ITAMs by Lyn serve as docking
sites for Src Homology 2 (SH2) domains of the PTK Syk. Syk binds to the
phosphorylated γ chains and becomes activated, via a conformational change, after being
phosphorylated by Lyn [31, 43]. For more information on Lyn and Syk please refer to
their dedicated sections below. Lyn and Syk activation mark a divergence point on
several signaling pathways that include the production of cytokines, eiscosanoids, growth
factors and, as will be the topic of the remainder of this discussion, degranulation [24,
11

42]. Following the degranulation pathway, activated Syk phosphorylates LAT (linker for
activation of T cells) at four distinct residues (Y171, Y191, Y226 and Y132) that allow it
to act as a scaffold for phospholipase Cγ1 (PLCγ1) [25, 50]. Once bound, PLCγ1 is
phosphorylated and activated by Syk, which is followed by the hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol-1,4,5-triphosphate (IP3) and
diacylglycerol (DAG) [25, 44]. The lipid mediator IP3 induces the release of intracellular
stores of Ca+2 via the IP3 receptor (Insp3R) found on the endoplasmic reticulum
membrane, while at the same time, DAG activates the serine/threonine protein kinase C
(PKC) [24, 25, 51,52]. Once endoplasmatic Ca+2 stores are emptied, the STIM1 protein,
a Ca+2 sensor found on the ER membrane, is relocated to the plasma membrane where it
interacts with store-operated Ca+2 (SOC) influx via Ca+2- release-activated Ca+2 (CRAC)
channels [53, 54]. This STIM1 protein possesses an amino-terminal EF hand Ca+2
binding domain that upon depletion of ER Ca+2 leads to rapid translocation to the plasma
membrane [55]. A study found that point mutations on the Ca+2 binding domain of
STIM1 resulted in failure to promote SOC influx of Ca+2 in response to ER store
depletion [54, 55]. Free Ca+2 and activated PKC act synergistically to assemble and aid
the machinery necessary for granule fusion with the membrane. PKC has been found to
phosphorylate both the light and heavy myosin chains, which contribute to the necessary
rearrangement of the cortical barrier in order for vesicle fusion to occur [56, 57].
Furthermore, it has also been shown that Ca+2/Calmudulin-dependent protein kinase II
phosphorylates also phosphorylates the heavy myosin chain during this exocytosis
process [57, 58].
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Exocytosis of the mediator-filled granules requires a complex machinery to fuse
the vesicle (granule) with the cell membrane. In mast cells this process is facilitated by
soluble NSF (N-ethyl-maleimidesensitive factor) attachment protein receptors (SNAREs)
that are found on the vesicle and the cell membrane [41, 59]. These SNAREs interact
with each other to form a complex that brings both membranes to a distance that will
allow for fusion to occur [59]. The membrane of the granule is equipped with a vesicleassociated membrane protein (VAMP), a SNARE that has been found in many isoforms
including VAMP 2, 3,7 or 8 [41, 60, 61]. It is not known, however, which isoform
participates specifically during IgE mediated degranulation. The cell membrane contains
SNAP 23, a ubiquitous SNARE, and syntaxin 4, another SNARE often associated with
IgE mediated degranulation [41,61]. Along with these SNAREs we also see many
accessory proteins such as NSF ATPase, for disassembly, and Rab GTPases involved in
regulation of the complex [41, 62]. In the presence of free calcium, a calcium sensor
(calmodulin or a synaptotagmin) binds directly to VAMP-2 and liberates it from its lipidbound state. Simultaneously, PKC phosphorylates SNAP 23 and syntaxin 4, which causes
a rearrangement of cytoskeletal components that interact with the freed VAMP-2 to form
the granule fusion complex [41, 59]. Once assembled, the presence of calcium allows for
the vesicle and the membrane to come to a distance of 2–3 Å, which energetically favors
the fusion of the membranes and the exocytosis of the mediators [59]. The PKC and
DAG complex are also known to regulate phospholipase D (PLD), which plays a vital
role in granule fusion with the cell membrane. PLD presents itself in two isoforms, PLD1
and PLD2 that are found on the granule and the plasma membrane, respectively [63].
1.6. Lyn Kinase
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Lyn is a known member of the Src family of intracellular membrane-associated
tyrosine kinases that are composed of a unique N-terminal myristoylation and
palmitoylation site, two homologous protein interaction domains (SH2 and SH3), and a
C-terminal kinase domain [64]. Studies have shown two important regulating residues
located on the kinase domain: Tyrosine (Y) residue 397, when phosphorylated, activates
kinase activity [65] while Y508, when phosphorylated, inactives Lyn [66]. Lyn normally
favors its inactive or closed conformation. This closed interaction is mediated through the
negative regulatory tyrosine (Y508) at the COOH-terminus that interacts with Lyn’s own
SH2 domain causing the protein to collapse into itself. A C-terminal Src kinase (Csk) is
responsible for phosphorylating Y508 and keeping Lyn in its inactive conformation [66].
Upon FcεRI stimulation, the balance between Csk and CD45 shifts, and the phosphatase
CD45 acts to reverse the phosphorylation of Y508 which allows Lyn’s SH2 domain to
bind to the receptor and cause a conformational change that exposes its activation loop
containing Y397. Phosphorylation of this residue activates the kinase activity of Lyn and
allows Lyn to phosphorylate the receptor, and eventually Syk [67]. The role of Lyn is
often described as a positive regulator of degranulation, but recent studies have shown
that Lyn plays an important negative regulation role as well. Lyn has been shown to
regulate the levels of PIP3 by inhibiting SH2 domain-containing inositol phosphatase-1
(SHIP-1) to control the extent of degranulation [67, 68]. Lyn as also been show to inhibit
the Fyn-dependent pathway by phosphorylating Cbp (C-terminal Src kinase (Csk)binding protein), allowing Csk to bind and to inhibit Fyn kinase via a mechanism similar
to that needed to maintain Lyn’s closed conformation [67, 69]. As a kinase vital to the
degranulation pathway, Lyn is a possible target for arsenic’s inhibitory effects.
14

1.7. Syk Kinase
Like Lyn, Syk is another key PTK involved in the degranulation pathway that
could be a possible target for arsenic inhibition. Syk is part of the SYK family of tyrosine
kinases that contain a C-terminal kinase domain and a tandem N-terminal SH2 domains
(Figure 2 A) [50, 70, 71]. ZAP-70 and Syk, both members of the SYK family of tyrosine
kinases, possess a linker region that separates these domains termed interdomain1,
however, Syk has an additional 23 amino acid linker region called interdomain B that
differentiates it from ZAP-70 [70, 71]. Due to these structural differences ZAP-70 and
Syk have important functional differences. Syk, unlike ZAP-70, is capable of
phosphorylating ITAMs without the help of Fyn or Lyn (Src kinases) [72]. Furthermore,
Syk has the ability to transphosphorylate neighboring Syk molecules while ZAP-70
requires activation via the phosphorylation of its Y493 residue by Src kinase to do so [73,
74]; transphosphorylation is a key aspect of signal amplification. Syk, as stated above in
the “degranulation” section, binds to phosphorylated γ chain ITAMs and becomes
activated via a conformational change in which the linker region folds the molecule so
that the SH2 domains are adjacent to the kinase domain. This conformation stabilizes the
structure of Syk and exposes residues Y519 and Y520 to Lyn phosphorylation or, if Lyn
is absent, to autophosphorylation [50, 71]. Phosphorylation of key resides Y317, Y342
and Y346 in the linker region allows for docking, and eventually the activation, of
downstream targets of Syk such as LAT, Vav and SLP-46 [29]. Syk is an essential kinase
in the activation of PLCγ and Ca+2 release: Zhang et al found that in Syk-deficient
TBIA2 (a cell line derived from RBL-2H3 cells) cells there was no appreciable tyrosine
phosphorylation of PLCγ1/2 and no detectable rise in intracellular Ca+2 upon receptor
15

aggregation. Furthermore, this study showed that transfection of Syk into these Sykdeficient cells rescued the activation of PLCγ and Ca+2 influx [75]. Another study by
Grodzki et al found that degranulation and cytokine production requires Syk as Syk
deficient RBLs were not able to degranulate or activate NFAT (nuclear factor of
activated T cells; transcription factors observed during Ca+2 fluctuations in degranulation)
[76].
A

B

C

Figure 2: Schematic Diagram of Syk and its States of Activity
(A) Linear structure of Syk with phosphorylated tyrosine residues mentioned in the text. (B)
Autoinhibited structure of Syk with phosphorylated Y317 negatively regulating the activity of
Syk. (C) Activated structure of Syk with phosphorylated Y130, Y519, and Y520, which
positively regulate Syk. Diagrams are adopted from Figure 1 of (De Castro, 2011). Created
using Adobe Illustrator CS5.
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As a vital player in degranulation, Syk is tightly regulated. Syk exists primarily in
its autoinhibitory state that is stabilized by a hydrophobic area composed of Pro(P)-396,
Y397 and Y474 in the kinase domain and Y319 in the linker region [77]. Upon coming
in contact with, and binding to, the Lyn-phosphorylated γ chain of the FcεRI receptor, the
hydrophobic interactions are disrupted, and Syk becomes activated. During the
interaction between the SH2 domains of Syk and the phosphorylated ITAMs of the
receptor, the residue Y130 on the linker region between the tandem SH2 domains of Syk
plays a vital role in regulating the successful association between the two.
Phosphorylation of Y130 dissociates Syk from the receptor by increasing the physical
distance between the SH2 domains and preventing appropriate binding to the
phosphorylated residues of the receptor [77]. Phosphorylation of Y317, found in
interdomain 2, has been shown to negatively regulate Syk activity as well. In a study
reviewed in de Castro et al, the expression of Syk-Y317F increased the activation of
PLCγ1/2 and enhanced the degranulation of the cells; replacing Y317 with a Phe showed
similar data as well (Figure 2 B) [77]. The positive regulation of Syk is varied and
extensive; however, the phosphorylation of residues, via autophosphorylation or another
kinase, Y519 and Y520 is necessary for signal transduction (Figure 2 C) [77].
Additionally, Zhang et al found that the replacement of either, or both, residues with Phe
did not inhibit kinase activity, but it did hinder signal transduction as the levels of total
tyrosine phosphorylation were considerably lower than the wild type controls [77, 78].
Much like Lyn, Syk is an essential PTK in the degranulation pathway that is strictly
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regulated and presents an attractive location for arsenic induced inhibition of mast cell
degranulation.
1.8. Current Work
The Gosse Lab has reported on the suppressive, dose-dependent effect of As on
mast cell degranulation at doses that are environmentally relevant [79]. They showed that
antigen activation of the cells was necessary for As to have any effect. Second, alternate
FcεRI cross-linking methods (other than multivalent antigen) produced similar
degranulation and As inhibition patterns [79]; this result provides evidence that As is not
directly disrupting the interaction between the receptor-bound IgE and the crosslinker
(either multivalent antigen or anti-IgE antibody). In order to assess whether arsenic’s
effect occurs downstream or upstream of calcium influx, Hutchinson and others used
calcium ionophore to achieve degranulation while bypassing the FcεRI receptor and the
early tyrosine phosphorylation cascade. Their results showed that As, in fact, did not
affect ionophore induced degranulation, and, thus, As must be affecting the signaling
pathway somewhere upstream of calcium influx [80]. Additional evidence for a
mechanism upstream of calcium influx was provided by Pelletier, who found that As
does not inhibit compound 48/80-mediated degranulation, suggesting that As does not
significantly disrupt phospholipase D activity, protein kinase C function, or the calcium
influx process itself [81]. Taken together with Hutchinson’s calcium ionophore data,
these data strongly suggest that arsenic’s effect in RBL cells is upstream of calcium
influx and likely involves the phosphorylation events of key signaling molecules, such as
Lyn or Syk kinase.
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1.9. Piceatannol
Piceatannol (3,4,3’5’ – tetrahydroxy-trans-stilbene) is a secondary natural product
isolated from Euphorbia lagascae seeds [82]. It has been previously identified as an
antileukemic compound and a protein-tyrosine phosphorylation inhibitor [82, 83, 84].
The structure of piceatannol is composed of a stilbene skeleton (a trans ethene double
bond flanked by a pair of phenyl group on both carbon atoms of the double bond; Figure
3 A) with hydroxide substituents found on carbons 3, 3’, 4 and 5’ that have a vital role on
its activity [81]. Using a β-hexosaminidase degranulation assay, similar to the one used in
our lab (described in “Methods” section), Matsuda et al found that not only is
piceatannol’s α-β double bond (Refer to Figure 3-A) important for activity, but the
position of the oxygen-containing constituents is essential for the potency of inhibition
[84]. Furthermore, this group found that substituting methoxyl groups in positions 3, 5’,
and 4’ while keeping a hydroxyl group on position 3’ increased the inhibitory activity of
piceatannol by nearly 12-fold [84].

A

B

Figure 3: Structure of Stilbene Skeleton and Piceatannol
(A) Structure of substituted stilbene skeleton showing the α-β bond and the positions of substituents. (B)
Structure of piceatannol. Sources: (A) Matsuda et al, 2004 [ref] (B) Sigma-Aldrich Corportation.
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Piceatannol’s mechanism of inhibition is still debated, but studies have shown it
to be a competitive inhibitor of protein-tyrosine kinase activity [82, 83, 85]. In one early
study, piceatannol isolates were incubated with p40, a protein-tyrosine kinase, and the
catalytic subunit of cAMP-dependent protein kinase to measure its effect on enzyme
activity. The study found that piceatannol competed with angiotensin 1 (a tyrosinecontaining peptide) for the substrate binding site of p40, but did not compete with the
substrate for the catalytic subunit of cAMP-dependent protein-serine kinase, a peptide
composed of Leu-Arg-Arg-Ala-Ser-Leu-Gly [82]. Geahlen et al concluded that
piceatannol selectively inhibits protein-tyrosine kinases by competing for the substrate
binding site through a structural resemblance to the tyrosine residue located on the
substrate, which lended some insight into future studies involving Syk and other protein
tyrosine kinases [82]. Years later after the discovery of Syk (also known as p72syk),
Oliver et al released a study describing piceatannol as a direct inhibitor of the PTK Syk
[83]. In this study they first found that both Lyn and Syk were inhibited by piceatannol;
however, the difference between the IC50 for Syk and Lyn was approximately 10-fold
with Syk being inhibited most readily [83]. Through the use of an anti-Tyr
immunoprecipitation assay, this study also concluded that a pretreatment with
piceatannol inhibited the tyrosine phosphorylation of Syk in a dose-dependent manner.
Oliver et al also carried out a similar study using whole RBL-2H3 cells and found similar
results. Additionally, these whole cell studies found that the PTK phosphorylation was
maximal within 1-2 min of antigen stimulation, the inhibition by piceatannol occurred
only upstream of calcium influx, and piceatannol did not inhibit the antigen-stimulated
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phosphorylation of the receptor β and γ subunits. Finally, Oliver et al elegantly showed
that piceatannol prevented antigen-induced ruffling and spreading (events often coupled
to antigen stimulation of mast cells; [83]), which replicated the results of a previous study
by Pfeiffer et al [86].
Herein, we will attempt to elucidate if there is a relationship between the arsenic
inhibition and the piceatannol inhibition of mast cell degranulation using a combination
experiment. These combination experiments will provide us with more evidence as to
whether Syk is the protein responsible for the arsenic inhibition.

2. Materials and Methods
2.1. Cell Culture
All experiments were carried out using Rat Basophilic Leukemia clone 2H3 (RBL2H3) cells. These cells were chosen due to their robust degranulation capabilities and
their constituent expression of FcεRI –IgE receptors (See “Introduction”). The RBL-2H3
were obtained as a gift from D. Holowka (Cornell University, Ithaca, NY, USA). These
cells were maintained in a monolayer culture within sterile, tissue culture treated
polystyrene flasks. Great care was taken to avoid plastics known to be possible sources of
endocrine disrupting chemicals (i.e bisphenol A, polyvinyl chloride,
polydimethylsiloxane, polyethylene terephthalate). While in culture, the cells were kept
immersed in Eagle’s minimal essential media (EMEM, with EBSS and L-Glutamine;
BioWhittaker Lonza) with 20% fetal bovine serum (FBS; Premium grade; Atlanta
Biologicals) and 10 µg/mL gentamicin sulfate (BioWhittaker Lonza) to protect the cells
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from infection. The culture conditions consisted of a constant temperature of 37°C and
levels of CO2 of 5% within a NAPCO Series 8000 WJ CO2 incubator (Thermo
Scientific). Flasks of cells were passed on a weekly basis using trypsin (0.05% porcine
trypsin with EDTA in HBSS; HyClone Laboratories Inc.), for up to three months. At
around 20 completed passages or upon the observation of undesired cell function due to
acquired genetic mutations (gross morphological changes, major swings in degranulation
capacity or other phenotypic changes), a new vial of cryogenically frozen RBLs was
thawed and the previous cell stock properly discarded. To prevent a mycoplasma
infection, all materials coming in contact with cell culture were sterilized using 70%
ethanol solution and all cell culture passages were carried out within a SteriGARD (The
Baker Company) tissue culture hood periodically cleaned with 70% ethanol.
Additionally, all buffers were sterile-filtered using Zap Cap filters (0.2 mm filter; PALL
corporation) and a mycoplasma detection test was performed monthly using the
MycoAlert mycoplasma detection kit (Lonza).
2.2. Reagents and buffers
2.2.1. Arsenic Stock Preparation
Arsenic (As) for all experiments was prepared by Lee Hutchinson on 4/30/2011,
as described in his thesis (Hutchinson Thesis, 2011). These stocks were concluded to be
stable because data previously published was successfully replicated with these stocks
(see “Results” section.) As described in Hutchinson’s graduate thesis: “Arsenic (As) for
all experiments was prepared under sterile conditions as 10 mM stocks of inorganic
sodium meta-arsenite (+3 oxidation state) (Baker Analyzed, 98.0% minimum, NaAsO2,
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CAS # 7784-46-5; JT Baker), and dissolved in cell culture water (sterile, reverse osmosis,
deionized, distilled Water for Cell Culture Applications; BioWhittaker Lonza). It was
next filtered with a 0.2 m syringe filter for sterility, aliquoted into sterile polypropylene
microfuge tubes, and frozen at -20°C until day of use. No stocks were re-frozen after
initial thawing for any experiment” [84].
2.2.2. Piceatannol Stock Preparation
Piceatannol (EMD Milipore) powder was purchased as 1mg vials and dissolved in
freshly made Tyrodes buffer. The solubility of piceatannol in water-based buffers is 0.5
mg/mL and 10 mg/mL in DMSO and Ethanol. Piceatannol was dissolved in the waterbased Tyrode’s buffer in an effort to prevent known interference effects from the DMSO
and ethanol. Due to its low solubility in water, however, great care was taken to ensure
the piceatannol was fully dissolved within the buffer. Furthermore, all experiments using
piceatannol included a NanoDrop Spectrophotometer (ND-1000; NanoDrop
Technologies) UV-Vis analysis prior to use in order to obtain the most accurate
concentration measurement. To calculate the concentration of piceatannol, a 0.1 mm path
length was used and the absorbance at 320nm was noted. The molar extinction coefficient
of piceatannol was calculated to be 0.045 µM-1 cm-1 from the data published by Li et al
[87]. These stocks were frozen at -20 °C until the day of use. Manufacturer’s instructions
of storage included storing the piceatannol stock under argon or likewise at -80°C. For
convenience, the piceatannol stocks were made immediately before use and discarded.
2.2.3. Tyrode’s Buffer Preparation
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Tyrode’s buffer was used as the vehicle for piceatannol and Bovine Serum
Albumin (BSA; Calbiochem) vehicle. It was extensively used throughout all experiments,
so stocks of 1L were made and stored at a temperature of 4°C. This buffer contained 135
mM NaCl (BioUltra; Sigma-Aldrich), 1.8mM CaCl2 (dihydrate; ACROS organics), 5mM
KCl (JT Baker), 1mM MgCl2 (hexahydrate; BDH), 5.6 mM D-(+)-glucose (anhydrous;
MP Biomedicals) and 20mM HEPES sodium salt (Ultra-pure; JT Baker). Stocks of NaCl,
CaCl2, KCl, and MgCl2 were made to concentrations of 0.5 M or 1M and kept at 4°C for
multiple preparations of the buffer. These stocks were dissolved using MiliQ ultra-pure
water (Milipore) and sterilized through a bottle-top filter (Corning). The buffer was
prepared through the combination of ingredients to their exact corresponding
concentration, diluted using MiliQ water, and sterilized using ZapCap 0.2mm filters. The
pH of the buffer was adjusted to 7.4 using concentrated HCl (12N; BDH Aristar).
2.3. Degranulation Assay
To quantify the extent of degranulation of RBL-2H3 following treatment, we used
a β-hexosaminidase activity assay. The enzyme β-hexosaminidase (β-hex) is a natural
product of degranulation and is released into the supernatant of culture cells. A synthetic
substrate of β-hex, 4-methylumbelliferyl-N-acetyl-D-glucosaminide (Calbiochem), is
cleaved to produce the fluorescent compound methylumbelliferrone that allows for a
direct measure of degranulation [35]. A fluorescent microplate reader (BioTek Synergy
2) was used in accordance to a previous assay as described by Naal et al [35].
For every degranulation experiment, RBL cells were harvested 2-4 days after
passage using a 5 min. (37°C) trypsinization treatment to dislodge the cells. Following an
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8 min centrifugation at 500 g, the cells were resuspended at a density of 0.5 x 10 6 cells/
mL in fresh media. The cells were then plated in a black flat-bottom, tissue-culture
treated, sterile 96-well plate (Greiner Bio-One) at a volume 100 µL per well. There
additions were randomized to minimize systematic error. Finally, the plate was incubated
overnight (12-16 hr.) at 5% CO2 and 37°C.
All degranulation experiments herein included the following treatments in
triplicates following IgE sensitization (discussed below). The addition of these treatments
was randomized and plates were flipped accordingly to eliminate plate position effects.
Each plate contained: (1) Antigen stimulation wells via DNP-BSA; (2) Spontaneous
release via Tyrodes-BSA (at 1 mg/mL BSA) buffer ; (3) Total β-hex release via Triton- X
100 (Surfact-Amps X-100, 10%, low carbonyl and peroxide; Thermo Scientific)
detergent cell lysis; (4) Background control wells with Tyrodes-BSA buffer and no cells.
Upon completion of the overnight incubation the spent media was discarded and
replaced with 100µL fresh media containing 0.1 µg/mL of anti-dinitrophenyl (DNP)
mouse IgE (monoclonal, clone SPE-7; Sigma-Aldrich). The plate was incubated for 1
hour at 37°C and 5% CO2 to allow for sensitization of the IgE receptors. After the IgE
sensitization, the media mixture was discarded and the plate was washed twice with
Tyrodes-BSA buffer (BT) to remove any IgE-media remnants.
Antigen treatments were solutions containing Tyrodes-BSA and multivalent
DNP-BSA at the appropriate concentration. DNP-BSA antigen is BSA that has been
conjugated with an average of 15 dinitrophenol (DNP) groups. The DNP- BSA was
prepared as described by Hardy et al [88] and donated by D. Holowka and B. Baird at
25

Cornell University. Wells containing cells to be stimulated received 200 µL of the
appropriate concentration of DNP-BSA antigen (concentrations varied depending on the
experiment). Wells designated as spontaneous received 200 µL of BT and those
designated as “total release” were exposed to 0.2% Triton at a volume of 200 µL. Wells
designated as background received 200 µL of BT and were used to measure background
fluorescence. After finalizing all additions, the plate was incubated in a cell incubator at
5% CO2 and 37°C for 1 hour.
After the 1 hour treatment, plates were placed on ice to halt degranulation. A
sample of 25 µL was removed from each treated well and combined with 100 µL of 1.2
mM β-hex substrate (4-methylumbelliferyl-N-acetyl-β-D-glucosaminide; dissolved in
acetate buffer) in a fresh, pre-cooled 96 well plate. The acetate buffer used to dissolve the
β-hex contains acetic acid (glacial, ACS and USP grade; BDH Aristar) at a concentration
of 0.12 M titrated to a pH of 4.4 with sodium hydroxide (10N; JT Baker). The fresh plate
containing the substrate and supernatants was incubated for 30 min at 37°C. At 30 min
the reaction in the wells was quenched by adding 200 µL of cold glycine-carbonate
buffer. The glycine-carbonate buffer contained 0.356 M glycine (Omnipur; EMD) and
0.444 M sodium carbonate (anhydrous, granular, ACS grade) titrated to pH of 10.
Following the 30 min incubation of the enzyme and the substrate we used a
microplate reader (Synergy 2; Biotek) to measure the activity of β-hex. The hydrolyzed
substate was excited using a 360/40 nm excitation filter and the fluorescence intensity
was read using 460/40 nm emission filter at normal speed and with a sensitivity setting of
40. Other settings included a distance of 7mm top optical offset and top 50% optics
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position. The raw data was processed by first subtracting the background fluorescence
value corresponding to wells with only BT. Second, the corrected values were divided by
the average total release (average raw fluorescence values of Triton-X 100 cell
supernatants) to yield a percent degranulation value.
Experiments using piceatannol included an extra step following IgE sensitization
but preceding antigen stimulation as described by Naal et al [35]. The piceatannol step
was a 10 minute exposure to 100 µL/well of varying piceatannol concentrations added
immediately after two BT washes. After the 10 minute incubation the piceatannol
treatment was discarded and the addition of 1 x 10-3 µg/mL DNP-BSA antigen followed.
Appropriate piceatannol-BT and piceatannol-Spontaneous controls were used for the
calculations of piceatannol containing treatments. These controls were necessary, because
piceatannol was shown to have some effect on both background fluorescence and
spontaneous release (See Results Section for more information).
Experiments using arsenic included a modification of the antigen addition step.
Arsenic was added into the antigen mixture prior to the addition to the plate. For the
wells not receiving arsenic, water (As vehicle) for cell culture (ultrafiltered, reverse
osmosis, deonized, distilled; Lonza) was added. After the addition of arsenic, or cell
water, to the antigen treatments, each corresponding well received 200 µL of the
appropriate treatment.
2.4. Phospho-Syk ELISA
The early results of piceatannol experiments provided some indirect evidence of
the involvement of the protein-tyrosine kinase, Syk, in arsenic inhibition of degranulation
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(See “Results” and “Discussion” sections for more information). With support from the
literature about arsenic disrupting phosphorylation patterns, we decided to seek a more
focused analysis of the phosphorylation of Syk under various treatments. After looking
through our options, we decided upon a Sandwich Phospho-Syk ELISA (Figure 4).
An ELISA, Enzyme-Linked Immunosorbent Assay, is a common biochemical
method used to screen for a specific antibody or to quantify an antigen in a sample [89].
There exist many variations including indirect, direct competitive, antibody-sandwich,
double antibody-sandwich, direct cellular, and indirect cellular ELISAs. Herein we will
describe the protocol of the ELISA used in our experiments, an antibody-sandwich
ELISA; for a description of the other types please see Hornbeck et al as referenced here
[90]. An antibody-sandwich ELISA is often regarded as the most sensitive ELISA
available with detection measurements between 2 and 5 times higher than the other types
[90]. A typical antibody-sandwich ELISA consists of a 96-well plate coated with a
capture antibody specific for the antigen in question. The wells are incubated with a test
solution containing the antigen (often a whole cell lysate or a blood sample) and washed
to remove unbound antigen. Later, a detection antibody conjugated to enzyme is added,
which binds to the antigen in question and acts as a developing agent in later steps. The
wells are once more washed to remove any unbound detection antibody and the addition
of the enzyme substrate is added. This substrate is hydrolyzed by the enzyme bound to
the detection antibody, which either fluoresces upon stimulation (fluorescent) or produces
a color that can be measured via absorption (chromogenic). Due to the 1:1 binding, the
extent of substrate hydrolysis as measured by a plate reader is proportional to the amount
of antigen present in the original sample [90].
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The PathScan® Phosho-Syk (panTyr) sandwich ELISA used in our experiments
was acquired from Cell Signaling Technologies (CST) as a kit. This ELISA was
manufactured to detect endogenous levels of phosphorylated Syk and included all
necessary materials for the ELISA protocol; it is a chromogenic ELISA. The kit included
a Syk antibody coated 96-well plate, separated into twelve 8-well strips for individual
experiments, the biotinylated phospho-tyrosine mouse detection antibody (primary
detection antibody specific for phosphor-tyrosine Syk), the HRP-linked streptavidin
(enzyme conjugated secondary antibody specific for the primary antibody), the TMB
substrate (HRP substrate), a proprietary STOP solution, a 20X wash buffer, a proprietary
sample diluent, a 10X cell lysis buffer (containing 20mM Tris (pH 7.5), 150mM NaCl,
1mM EDTA, 1mM EGTA, 1% Triton X-100 [lysing detergent], 2.5mM sodium
pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1µg/mL leupeptin) and sealing
tape to prevent vaporization during incubation times. The kit was instructed to be stored
at 4°C with the exception of the 10X cell lysis, which was instructed to be stored under 20°C.
The protocol that will follow is a modified version of the CST provided protocol.
The lysates were extracted from whole RBL-2H3 cells passed and cared for as described
above in the “Cell Culture” section. RBL cells were harvested 3-6 days after passage
using a 5 min. (37°C) trypsinization treatment to dislodge the cells. Following an 8 min
centrifugation at 500xg, the cells were resuspended at a density of 1.75 x 106 cells/ mL in
fresh media. The cells were then plated on 10cm tissue-culture treated, sterile dishes
(Cellstar, Acquired from VWR International) at a volume of 5 mL per well (final cell
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density of 8.75x106 cells per dish). Finally, the dishes were incubated overnight (12-16
hr.) at 5% CO2 and 37°C.

Figure 4: Summary of ELISA protocol
Schematic of Phospho-Syk ELISA protocol used herein. Created using Adobe Illustrator CS5

Following the overnight incubation, each dish was checked to ensure a cell
confluence between 80 and 90%. The cell media was then immediately discarded and
replaced with fresh media containing anti-DNP IgE (Sigma) at a final concentration of
0.1 µg/mL. The dishes were incubated for 1hr at 5% CO2 and 37°C. After the 1hr IgEsensitization, the spent IgE-media mixture was discarded and washed twice with 5 mL of
BSA-Tyrodes to remove any unbound IgE. The 5 mL treatements added next included
either BSA-Tyrodes for the unstimulated controls or DNP-BSA antigen at 1µg/mL for
stimulated samples. The dishes were incubated for either 5 mins in a bacterial incubator
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at 37°C. Immediately after the incubation, the dishes were removed, placed on ice,
washed once with ice-cold PBS (4-5mL) and lysed with 0.5 mL of ice-cold 1X lysis
buffer containing PMSF for 5 min. The 10X lysis buffer provided in the kit was thawed
at 25°C and diluted with purified Mili-Q water before use; Phenylmethanesulfonyl
fluoride solution (PMSF; 100mM stock dissolved in Ethanol; Sigma-Aldrich) was added
at a concentration of 1mM immediately prior to lysis buffer addition. Following the lysis
incubation the cells were harvested into pre-cooled 2 mL microcentrifuge tubes by using
a sterile cell scrapper. Each lysate was then sonicated on ice by introducing a clean
sonicating probe directly into the lysate. The sonicator was set at 35 watt output and each
lysate was sonicated 2 times for 5 sec each time with a 10 sec break in between. Finally,
the sonicated lysates were spun down at 14,000 x rpm for 10 min at 4°C. A volume of
100 µL of the clear supernatants from the centrifuged samples were separated from their
pellets and placed in new pre-cooled tubes containing 100 µL sample diluent (provided in
the CST kit). After a brief vortex, 100 µL of the diluted sample were placed in their
appropriate ELISA wells, sealed with tape and incubated overnight (16-20 hrs) at 4°C.
The following day, the plate contents were discarded and each well was washed
with 4 times with 200 µL of 1X wash buffer (20X wash buffer provided by CST was
diluted using purified Mili-Q water). The washes were followed by an addition of 100 µL
of the biotinylated phospho-tyrosine mouse detection antibody to each well. The plate
was sealed and incubated at 37°C for 1hr. Following the incubation the well contents
were discarded and each well was washed 4 times with 200 µL of 1X wash buffer. Next,
100 µL of the HRP-linked secondary antibody were added to each well, the plate was
sealed, and incubated at 37°C for 30 min. Once more, the contents of each well were
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discarded and the wells were washed with 200 µL of 1X wash buffer. A volume of 100
µL of the TMB substrate was added and the plate was sealed and incubated for 10min at
37°C. After this 10 min incubation, and immediately before reading, 100 µL of the STOP
solution were added to each well. An initial blue color upon addition of TMB substrate
indicated a positive reaction, which then changed to yellow when the STOP solution was
added. The plate was immediately placed in a BioTek Synergy 2 microplate reader and
the absorbance of each well as measured at 450 nm.
Experiments using arsenic included a modification of the antigen addition step.
Arsenic was added into the antigen mixture prior to the addition to the dishes. For the
dishes wells not receiving arsenic, water (As vehicle) for cell culture (ultrafiltered,
reverse osmosis, deonized, distilled; Lonza) was added. After the addition of arsenic, or
cell water, to the antigen treatments, each corresponding dishes received 5mL of the
appropriate treatment as described in the manufacturer’s ELISA protocol.

3. Results
3.1. Establishment of 1 hr Piceatannol-Arsenic Combination Assay
The piceatannol-arsenic combination assays followed the same structure as the
arsenic experiments for which data has been previously published [79] with the exception
of the addition of a 10 min piceatannol addition step prior to antigen stimulation [35]. In
order to observe a possible effect of this extra step on normal mast cell degranulation
(monitored via antigen dose response experiments) we carried out an antigen dose
response with a 10 min mock piceatannol step. This mock-piceatannol step was a 10
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minute exposure to 100 µL of warmed Tyrode’s Buffer added immediately after two BT
washes. After the 10 minute incubation the mock-piceatannol treatment was discarded
and the addition of various antigen concentrations followed. Appropriate Tyrode’s-BT
and Tyrode’s-Spontaneous controls were used for the calculations of piceatannol
containing treatments. The mock-piceatannol antigen dose response (Figure 5-A) elicited
a maximal degranulation (at 0.1 µg/mL DNP-BSA antigen) of 41.16% - 46.46% (95%
CL) and spontaneous levels of 2.3% ± 0.4 (SD), while a typical antigen dose response
(without the extra 10 min pre-stimulation exposure; Figure 5-B) elicited a maximal
degranulation (at 0.1 µg/mL DNP-BSA antigen) of 35.61% - 37.93% (95% CL) and
spontaneous levels of 1.4 % ± 0.4 (SD). From these results we concluded that the
addition of the additional 10 min exposure could be having an effect on the degranulation
of RBLs, however, this data represents only a pair of separate experiments so conclusions
must be made carefully. Furthermore, the maximal degranulation for the experiment
including the mock and the one without (41% and 38%) are similar enough as to
conclude that if there is an effect due to this extra step, then it is a small and will likely be
abolished by implementing the corresponding controls. It needs to be noted that
experiments with cell culture will inherently have variation from experiment to
experiment depending on the number of passages that have been carried out on a
particular thaw, the day the cells are harvested, and the time the cells spend in culture
(unpublished observations).
Previously published data from this lab revealed that lower concentrations of
antigen yielded the strongest arsenic dampening effect [79]. Keeping this in mind, we
carried out several experiments involving a 10 min piceatannol mock step prior to
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stimulation with (A) 0.00002 µg/mL, (B) 0.00004 µg/mL, and (C) 0.001 µg/mL DNPBSA antigen (Figure 6). Each experiment also received varying arsenic concentrations.
Low concentrations of antigen with the 10 min mock piceatannol step resulted in
unreliable and highly variable results, likely due to the low extent of degranulation
observed (less than 3% degranulation). The maximal degranulation for the lower antigen
concentrations without arsenic was at, or around, the same level as spontaneous
degranulation. A higher antigen concentration (0.001 µg/mL) was thus chosen. The
outcome was a replication of the arsenic inhibition pattern observed in the Hutchinson et
al [79]. In the absence of As, the absolute level of degranulation was 26% ± 3% (SD);
untreated cells yielded spontaneous degranulation levels of 3.1% ±0.5 (SD) (Figure 6).
This absolute level of degranulation is comparable to the level elicited by 0.0004 µg/mL
DNP-BSA in previously published results (Compare 26% ± 3% (SD) observed in Figure
6 to 25% ± 1% (SD) observed in Hutchinson et al) [79]. At the highest concentration of
arsenic of 750ppb, our experiments showed a ~31% inhibition of degranulation (Figure
6) that is comparable to the ~37% (0.63-fold inhibition) inhibition observed in
Hutchinson et al for experiments eliciting similar absolute levels of degranulation in the
absence of As [79]. These results affirmed the potency of the arsenic stock, and it also
enabled us to choose the antigen concentration that that was to be used for all piceatannol
experiments.
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Figure 5: Effects of 10 min Exposure Step Pre-Stimulation
RBL cells were cultured overnight and washed twice with Tyrodes-BSA. Cells were either (A)
exposed to warm Tyrode’s buffer for 10 minutes prior to antigen stimulation or (B) lacked this
additional 10 min exposure step. The β-hexosaminidase release (expressed as a percentage of
degranulation) is plotted against the log10 [DNP-BSA]. (C) is a combined plot of (A) and (B)
with their respective 95% CI as dashed lines. Graphs are expressed as means ± SD; two
experiments for each graph; three replicates per dose per experiment. Best fit line plotted was
calculated using the “Sigmoidal regression (variable slope)” function in GraphPad Prism
version 4.
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Figure 6: Optimization of Antigen Concentrations for 1 hr Piceatannol-Arsenic Combination
Assays.
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cell were then exposed
to warm Tyrode’s (piceatannol mock) for 10 min prior to stimulation with 0.001 µg/mL DNP-BSA
for 1 hr. Each experiment also included a simultaneous exposure to varying doses of arsenic during
this 1 hr stimulation period. One way ANOVA tests were implemented and statistical significance
when compared to 0 ppb is symbolized as ** for p-values less than 0.001.

3.2. Effects of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated
Degranulation
An investigation of the effect of piceatannol-arsenic co-exposure was performed.
Using varying doses of piceatannol during a 10 min pre-stimulation exposure as followed
by a 1hr antigen ± 750ppb arsenic exposure, it was found that 200 µM piceatannol, in
combination with arsenic, dampened degranulation by ~77% while the exposure to
arsenic alone produced a ~23% inhibition of degranulation (Figure 7). In the absence of
arsenic and piceatannol, these experiments elicited an absolute level of degranulation of
35.2% ± 3% (SD) and spontaneous levels of 5.2% ± 0.7% (SD). This absolute level of
degranulation is comparable to the level elicited by 0.0004 µg/mL DNP-BSA in
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previously published results (Compare 35.2% ± 3% (SD) observed in Figure 7 to 25% ±
1% (SD) observed in Hutchinson et al) [79]. These results also fall in line with previous
data shown in this report of 26% ± 3% (SD) (Figure 6). At the highest concentration of
arsenic of 750ppb without piceatannol, our experiments showed an average of ~24%
inhibition of degranulation that is comparable to the ~37% (0.63-fold inhibition)
inhibition observed in Hutchinson et al [79] and ~31% reported earlier in this thesis
(Figure 6) for experiments eliciting similar absolute levels of degranulation. The arsenic
inhibition of degranulation was consistent throughout the doses 0 µM, 20µM, and 100
µM piceatannol (inhibitions were ~26%, ~28%, ~29% respectively), however, at 200 µM
piceatannol this inhibition was only ~12% (Calculated based upon the change in
inhibition [No As – As] for each piceatannol dose) (Figure 7). In the absence of arsenic,
the piceatannol inhibition of degranulation for doses 20µM, 100 µM, and 200 µM was
~13%, ~37%, and ~65% respectively (Figure 7). Co-exposure to 750 ppb arsenic and
20µM, 100 µM, and 200 µM piceatannol inhibited degranulation by ~41%, ~66%, ~77%
respectively (Figure 7).
Piceatannol did show some concerning effects on spontaneous degranulation,
however. Although insignificant in the combined data, individual spontaneous results
showed piceatannol-arsenic co-exposure induced inhibition of up to 10% that should be
noted (Figure 8-A). All raw fluorescence values were compared to their respective
controls (i.e piceatannol-arsenic exposures were compared to arsenic with no piceatannol
background samples; piceatannol only exposures were compared to no arsenic-no
piceatannol background samples) when calculating percent degranulation to avoid any
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possible piceatannol induced interference of background fluorescence. Still, it was found
piceatannol at 200 µM decreasing background fluorescence by 20% when compared to
Tyrode’s-BSA sample (Figure 8-B).
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B

Figure 7: Effects of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated
Degranulation
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cell were then exposed
to piceatannol at the indicated doses for 10 min prior to stimulation with 0.001 µg/mL DNP-BSA
and simultaneous exposure to 750ppb for 1 hr. (A) Combined data, (B) Normalized data reported in
(A): Values were normalized to . In graphs (A) and (B) percent of degranulation is plotted against
the concentration of piceatannol. The results of antigen stimulated cells exposed to no arsenic and
no piceatannol (No As, 0 uM piceatannol . (A) was evaluated using individual t-tests by comparing
the As to No As treatments for each piceatannol concentration. * and *** represent p-values of less
than 0.05 and 0.0001 respectively.
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B

Figure 8: Effects of 200 µM Piceatannol on Spontaneous Release and Background Fluorescence
Effects of 200 µM piceatannol on (A): Spontaneous release and (B) Background fluorescence. (A) RBL
cells were cultured overnight and washed twice with Tyrode’s buffer. Cells were then exposed to
piceatannol at the indicated doses for 10 min prior to BSA- Tyrode’s addition (as opposed to antigen
stimulation). (B) Wells with no plated cells were washed twice with Tyrode’s buffer. Wells were then
exposed either warm Tyrode’s (BT bar) or 200 µM piceatannol for 10 min prior to BSA-Tyrode’s
exposure for 1hr. Unpaired t-tests were run to evaluate significance: ns= not significant; ***= p-value <
0.0001.
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3.3. Establishment of Phospho-Syk ELISA Experiments
The protocol for the Phospho-Syk ELISA experiments was heavily based upon the
reference protocol provided with the PathScan® Phosho-Syk (panTyr) kit from Cell
Signaling Technologies. Still, many individual steps in this protocol had to be tailored to
our system (See Figure 9 for all optimizations). The first of these steps was the sonication
procedure. Cells were lysed as described in the “Methods” section, scraped off the
dishes, and sonicated at 35Watts at different time intervals. The lysates were inspected
for live cells and counted under the microscope using trypan blue dye. Ultimately, it was
found that sonicating the lysates at 35 Watts 3 times for 5 seconds, with 10 seconds
breaks in between, resulted in the fastest sonication procedure to fully lyse the cells
(results not shown). Due to the fragility of the phosphorylation state of these proteins, it
was crucial to ensure that steps following the stimulation of the cells were carried out as
quickly as possible. Another step that was evaluated during the development of the
protocol was the correct dilution of the lysates and the incubation time of the STOP
solution following the incubation of the TMB substrate. The ELISA kit provided a
sample diluent, whose ingredients are proprietary, and recommended a 1:1 dilution of the
processed lysate prior to addition to the ELISA plate. Using the procedure described in
the “Methods” section, it was found that the 1:1 dilution elicited the most robust percent
increase in antigen-stimulated Syk phosphorylation with an average percent increase over
control (BT) of 25% for all time points (Figure 10-B). Furthermore, immediate reading of
the sample following the addition of STOP (0 min columns; Figure 10 A-C), as compared
to later timeframes, showed the highest percent increase in Syk phosphorylation for
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undiluted and 1:2 diluted samples with 14.57% ± 0.93% (SD) and 17.17% respectively
(Figure 10-A and C).
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Parameter Tested
Cell density to be cultured in
10cm dishes that produces 8090% confluence following
overnight incubation

Extent of lysis following various
[detergent] in 5 min lysis buffer
incubation without scraping

Extent of lysis following various
[detergent] in 5 min lysis buffer
incubation with scraping

Sonication of cell lysates that
result in no visible whole cells or
cellular fragments

Experimental Result
Densities tested:
11.375x106 cells/dish: confluence
falls within 80-90%
9.625x106 cells/dish: confluence
was lower than 80%
8.75x106 cells/dish: considerably
underconfluent
Tested:
0.2% TX: low cell lysis
0.5% TX: low cell lysis
1% TX: moderate cell lysis
Tested:
0.2% TX: low cell lysis; almost
undisturbed cell lawn
0.5% TX: moderate cell lysis;
cells looked stressed and some
were lysed
1% TX: high cell lysis; small
number of viable cells observed
Tested:
Sonicated 3 times for 5 sec each
@ intensity of 25 W: whole cells
obseved
Sonicated 3 times for 10 sec each
@ intensity of 25 W: whole cells
observed
Sonicated 3 times for 5 sec @
intensity of 35 W: no whole cells,
some fragments
Sonicated 3 times for 10 sec @
intensity of 35 W: no whole cells,
some fragments

Extent of dilution of cell lysate
(immediate reading following
STOP addition)

Tested:
Undiluted: 14.5% increase over
control
1:1 dilution: 23% increase over
control
1:2 dilution: 17.1% increase over
control

Extent of STOP incubation time
for 1:1 diluted lysates

Tested:
0 min: 23% increase over control
5 min: 25% increase over control
20 min: 24% increase over
control

Figure 9: Optimization of the Phospho-Syk ELISA Protocol
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Conclusion

Cells will be cultured at
11.375x106 cells per dish for 1620 hrs to achieve 80-90%.

As recommended by CST, 1%
TX lysis buffer elicits the highest
extent of lysis, however, scraping
maybe be needed as there was not
enough lysis observed

The lysis procedure using a lysis
buffer with 1% TX and scraping
resulted in the highest extend of
lysis

The final sonication procedure
was chosen to have an intensity
of 35W repeated 3 times for
duration of 5 secs each. This was
chosen over the similar procedure
at 10 sec as no difference was
observed between these
treatments

Reading immediately following
the addition of STOP solution (as
recommended by CST), it was
found that a 1:1 dilution of lysate
with the manufacturer’s diluent
produced the highest percent
increase over control in phosphoSyk
Samples diluted 1:1 with the
manufacturer’s diluent produced
the same percent increase over
control in phosphor-Syk
regardless of the extent of STOP
incubation time. Immediate
reading was chosen as
recommended by CST.

A

B

C

Figure 10: Investigation of the Effect of Dilution and Incubation Time of the STOP Solution on
Phosphor-Syk Phosphorylation as Measured via ELISA.
Lysate samples were prepared as described in “Methods” Section. Each 100 µL lysate sample was added
to the ELISA plate either (A) undiluted, (B) diluted 1:1 with sample diluent, or (C) diluted 1:2 with
sample diluent. Samples were plated in duplicates, with the exception of (C) which is only based on one
sample; their error bars represent SD.
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3.4. Investigation of the SYK Gene in Human and Rat
The plates provided with the PathScan® Phosho-Syk (panTyr) kit from Cell
Signaling Technologies were coated with anti- human Syk antibodies. Since the cells we
used for our experiments were rat cells, we aimed to ensure that there would be
appropriate cross-reactivity between the RBL cell’ rat Syk and the kit’s anti-human
antibodies. Thus, we carried out an alignment of the SYK gene in human (Homo sapiens)
and that of rat (Rattus norvegicus). An alignment analysis of the long human isoform
SYK and rat SYK in ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2) using the
default settings was carried out and resulted in 91% homology at the protein level and
84% at the nucleotide level (Figures 11 and 12) (Juyoung Shim, unpublished analysis).
Such high homology values allowed us to conclude that there is a high probability that
anti-human Syk antibodies could in fact recognize rat Syk proteins.
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A
MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK
AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF
EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ
IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL
VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPK
PGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRP
KEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE
ANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSM
GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA
PECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPRE
MYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN\

B
MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK
AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF
EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ
IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL
VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPASSPAQGNRQESTVSFNPY
EPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFG
TVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAES
WMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLV
TQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMW
EAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVE
LRLRNYYYDVVN

C
MAGNAVDNANHLTYFFGNITREEAEDYLVQGGMTDGLYLLRQSRNYLGGFALSVAHNRKAHHYTIERELN
GTYAISGGRAHASPADLCHYHSQEPEGLVCLLKKPFNRPPGVQPKTGPFEDLKENLIREYVKQTWNLQGQ
ALEQAIISQKPQLEKLIATTAHEKMPWFHGNISRDESEQTVLIGSKTNGKFLIRARDNNGSFALCLLHEG
KVLHYRIDRDKTGKLSIPEGKKFDTLWQLVEHYSYKPDGLLRVLTVPCQKIGVQMGHPGSSNAHPVTWSP
GGIISRIKSYSFPKPGHKKPPPPQGSRPESTVSFNPYEPTGGAWGPDRGLQREALPMDTEVYESPYADPE
EIRPKEVYLDRKLLTLEDNELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQ
LDNPYIVRMIGICEAESWMLVMEMAAWGPLNKYLQQNRHIKDKNIIELVHQVSMGMKYLEESNFVHRDLA
ARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYFKFSSKSDVWSFGVLMWEAF
SYGQKPYRGMKGSEVTAMLEKGERMGCPPGCPREMYDLMFLCWTYDVENRPGFAAVELRLRNYYYDVVN

Figure 11: Raw Nucleotide Sequences of Human and Rat SYK Genes
(A) |P43405|KSYK_HUMAN Tyrosine-protein kinase SYK OS=Homo sapiens GN=SYK PE=1
SV=1 635aa
(B) |P43405-2|KSYK_HUMAN Isoform Short of Tyrosine-protein kinase SYK OS=Homo
sapiens GN=SYK 612aa (Short Isoform)
(C) |NP_036890.1| tyrosine-protein kinase SYK [Rattus norvegicus] 629aa
All sequences were acquired from the National Center for Biotechnology Information (NCBI).
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Human
Rat

MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK 60
MAGN-AVDNANHLTYFFGNITREEAEDYLVQGGMTDGLYLLRQSRNYLGGFALSVAHNRK 59
**.. .*.****.:*******************:**********************.**

Human
Rat

AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF 120
AHHYTIERELNGTYAISGGRAHASPADLCHYHSQEPEGLVCLLKKPFNRPPGVQPKTGPF 119
****************:***:**************.:************* *********

Human
Rat

EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ 180
EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGNISRDESEQ 179
***************************************************:***:****

Human
Rat

IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL 240
TVLIGSKTNGKFLIRARDNNGSFALCLLHEGKVLHYRIDRDKTGKLSIPEGKKFDTLWQL 239
*********************:****************:********************

Human
Rat

VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPK 300
VEHYSYKPDGLLRVLTVPCQKIGVQ-----MGHPGSSNAHPVTWSPGGIISRIKSYSFPK 294
*******.***************.*
*:* ..:**.***.**************

Human
Rat

PGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRP 360
PGHKKPPPPQGSRPESTVSFNPYEPTGGAWGPDRGLQREALPMDTEVYESPYADPEEIRP 354
***:*..*.**.* *********** ..*..*:* ************************

Human
Rat

KEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE 420
KEVYLDRKLLTLEDNELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE 414
**************:*********************************************

Human
Rat

ANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSM 480
ANVMQQLDNPYIVRMIGICEAESWMLVMEMAAWGPLNKYLQQNRHIKDKNIIELVHQVSM 474
******************************* ************:**************

Human
Rat

GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA 540
GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA 534
************************************************************

Human
Rat

PECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPRE 600
PECINYFKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPPGCPRE 594
******:***********************************************.*****

Human
Rat

MYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN 635
MYDLMFLCWTYDVENRPGFAAVELRLRNYYYDVVN 629
***** *****************************

Figure 12: Alignment of long Human Isoform SYK and rat SYK
A multiple sequence alignment was carried out using ClustalW2 version 2.1 and the default
settings. The yellow highlight is intended to call attention to tyrosine residues 525 and 526
(see Introduction section for more details on these residues).
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3.5. Effects of 750 ppb Arsenic on Syk Phosphorylation as Measured via
Phospho-Syk ELISA
As of the writing of this thesis, the optimization of the ELISA protocol is still a work
in progress. Early experiments have had promising results that may point to a pattern of
Syk phosphorylation deficiency in the presence of arsenic. An experiment involving
monoclonal IgE sensitized RBLs stimulated with 0.001 µg/mL DNP-BSA antigen and
treated with 750 ppb arsenic resulted in a pattern of detectable phospho-Syk dampening.
As shown in Figure 13A, there is a clear increase in absorbance of antigen-stimulated
Syk phosphorylation and then the subsequent decrease likely due to As interference of
phosphorylation of Syk. Further processing of the raw absorbance readings demonstrated
a clear percent increase in phosphorylated Syk of 30% ± 11% (avg. error; Figure 13 B).
When exposed to 750 ppb As, the levels of phosphorylated Syk decreased to 18% ± 5%
(avg. error; Figure 13 B), which indicates a decrease of ~42% Syk phosphorylation likely
induced by As. However, a one-tailed unpaired t-test carried out with GraphPad Prism
showed no statistical significance with a p-value of 0.1801.
As stated earlier, the fragility of phosphorylated proteins requires a swift management
and implementation of stimulation and lysis steps. It is these steps that we suspect to be
the culprit to the inconsistency in the data and so further optimization of these steps must
be carried out before they can produce reliable data. During these optimization
experiments, it was proposed that the old arsenic stock could have lost its potency over
time (stocks were originally made in 04/30/2011 by Lee Hutchinson). New stocks were
thus prepared and their potency was evaluated (Figure 14). At antigen concentrations of
0.0004 µg/mL (Figure 14-A) and 0.00016 µg/mL (Figure 14-B), the maximal
48

degranulation values (0 ppb As) were 145% ± 1 (SD) and 6.0% ± 0.8% (SD),
respectively, and spontaneous degranulation levels of 7% ± 1% (SD). The maximal
inhibition elicited by 750 ppb arsenic was ~37% and ~44%, respectively. Spontaneous
degranulation was not affected by arsenic (Figure 14-C). These results resemble those
published in Hutchinson et al by exhibiting a similar dose response inhibition pattern, so
the potency of the new arsenic stock was confirmed.
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A

B

Figure 13: Effects of 750 ppb Arsenic on Phosphorylated Syk as Measured via Phosho-Syk
(panTyr) Sandwich ELISA
Effects of 750 ppb Arsenic on Phosphorylated Syk as Measured via PathScan® Phosho-Syk
(panTyr) sandwich ELISA from Cell Signaling Tech. RBL cells were stimulated with 0.001
µg/mL DNP-BSA antigen and simultaneously treated with 750 ppb As for one hour. Cells were
then lysed and diluted 1:1 with sample diluent prior to being added to the ELISA plate. For the
complete ELISA protocol see the “Methods” section. (A) Raw absorbance values of Spontaneous
(BT; non-stimulated), antigen only, and antigen and arsenic were done in duplicate; Error bars
show average error. (B) Percent increase of antigen and antigen & arsenic treatments, over the
non-stimulated spontaneous control. (B) is the processed form of the data shown in (A).
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B

C

Figure 14: Investigation of New Arsenic Stock Potency
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cells were then stimulated
with (A) 0.0004 µg/mL, (B) 0.00016 µg/mL, and (C) Tyrode’s buffer (for spontaneous degranulation).
Experiments were in done in triplicates; error bars signify ± SD.
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4. Discussion
4.1. Discussion of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated
Degranulation Experiments
While establishing the piceatannol-arsenic combination assay it was found that the
additional 10-min step needed to expose the cell to piceatannol could be having an effect
on the typical degranulation of RBLs. It must kept in mind that these conclusions were
drawn from only two experiments done on different days and using cells that, although
were from the same thaw, were not from the same passage. Still, as it is a commended
research practice, the controls used to analyze all data included this extra step regardless
of whether the effect is real or just an artifact. This meant that spontaneous wells,
background wells, and TX-lysis wells all included this additional 10 min piceatannol
exposure. Furthermore, the results from the optimization experiments of the antigen
concentration, which included the extra 10 min piceatannol mock step, helped to ease our
initial concerns. The 0.001 µg/mL concentration of DNP-BSA experiments (Figure 6-C)
that exhibited an absolute level of degranulation of 26% ± 3% (SD) in the absence of As
showed a comparable inhibition pattern shown in Hutchinson et al [79]. Additionally, and
more importantly, the maximal inhibition at this concentration (elicited by 750ppb) was
comparable to the inhibition elicited by the same exposure to arsenic at 0.0004 µg/mL
DNP-BSA antigen. These experiments can be compared, because their absolute levels of
degranulation reached a similar degree (compare 26% ± 3% (SD) observed in Figure 6to
25% ± 1% (SD) observed in Hutchinson et al) [79]. In that same publication, these
experiments with comparable levels of absolute degranulation experienced a maximum
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degree of arsenic-induced inhibition of degranulation at 750 ppb with ~37% (0.63-fold)
inhibition when compared to its appropriate 0 ppb samples [79]. Likewise, our
experiments reported here showed a ~31% inhibition of degranulation (Figure 6) that is
comparable to those experiments mentioned above. These results assured us that the
potency of our arsenic stock was still at the desired level, and that an antigen
concentration of 0.001 µg/mL elicited a level of absolute degranulation for this particular
thaw of cells that is comparable to already published data. Furthermore, we concluded
then that, by controlling any possible effect of the extra 10 min exposure, we could
replicate the previously reported arsenic dose response inhibition of degranulation and
thus our piceatannol-arsenic combination assays could be accurately used to investigate
the possibility of arsenics involvement in the early tyrosine phosphorylation pathway.
The addition of piceatannol to our arsenic experiments showed a robust and clear
inhibition of degranulation. This potent combined inhibition of ~77% at arsenic
concentrations of 750 ppb and exposure to 200 µM piceatannol for the piceatannolarsenic combination assays appears to point to an additive mechanism of inhibition.
Exposure to arsenic alone produced an average of ~24% inhibition of degranulation
(Figure 7 A andB) while piceatannol, the absence of arsenic, produced a maximal
inhibition of degranulation of ~65%. Since only a dose of 750 ppb arsenic was used in
these combination experiments, it was expected for arsenic to inhibit all samples equally.
This was the case for 3 out of the 4 treatments groups. At 200 µM piceatannol and 750
ppb As, arsenic only attributed ~12% of the inhibition while at all other piceatannol doses
the arsenic inhibition remained at constant levels (compare ~12% at 200 µM and 750 ppb
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As to ~26%, ~28%, ~29% at 0 µM (and 750 pbb As), 20µM (and 750 ppb As), and 100
µM (and 750 ppb As) piceatannol respectively) (Figure 7). We suspect that the low levels
of degranulation of cells treated with 200 µM and 750 ppb As could be help culprit to this
erratic behavior. Cells exposed to this treatment elicited degranulation of 8% ± 1% (SD)
(Figure 7), which is along spontaneous levels reported as 5% ± 1% (SD) for these
experiments (spontaneous data not shown). At such low levels, it has been observed that
degranulation patterns become erratic and unpredictable, which could explain why the
arsenic contributions to inhibition at such high levels of piceatannol deviate from the
other treatments (unpublished observations). In the absence of arsenic, the piceatannol
inhibition contributed to the inhibition of degranulation in a dose dependent manner.
Doses of piceatannol of 20µM, 100 µM, and 200 µM (confirmed using UV-Vis analysis;
see Results section) resulted in ~13%, ~37%, and ~65%, respectively, inhibition of
degranulation (Figure 7).
Co-exposure to 750 ppb arsenic and 20µM, 100 µM, and 200 µM piceatannol
inhibited degranulation by ~41%, ~66%, ~77% respectively (Figure 7). This inhibition
occurred in an additive fashion with 750ppb arsenic contributing a consistent inhibition
of ~24% (with the exception of 200 µM) and piceatannol contributing the rest. This
additive inhibition of degranulation could point to a few possible mechanisms of action.
Since piceatannol acts directly at the substrate binding site of Syk to inhibit it [83, 84] it
is possible that arsenic could be doing the same. Arsenate, as previously stated, has been
shown to compete with free phosphate uptake and binding during phosphorylation
reactions [13, 16, 18, 91, 92, 93], which lends support to a mechanism in which
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piceatannol and arsenic could be collectively inhibiting Syk by competing for the tyrosine
binding site of phosphate. Alternatively, it is possible that while piceatannol blocks the
binding of phosphate to these tyrosine residues, arsenic could be interfering with the
uptake of free-phosphate by the cell. Finally, it is also possible that arsenic could be
acting indirectly to inhibit Syk by stimulating the production of ROS, which are
detrimental for the activity of kinases [14].
4.2. Discussion of the Phospho-Syk ELISA Experiments
Optimization of the Phospho-Syk ELISA protocol has proven to be laborious, yet
insightful process for our lab. We were able to eliminate our old arsenic stock as being a
possible source of error, as the freshly made stock inhibited degranulation in a similar
fashion as previously published data [79] and previous data reported here (Figure 4). The
analysis of the human and rat SYK genes also provided valuable insight while
eliminating a possible source of error in the optimization of our experiments. The high
degree of homology between these genes, and the proteins they produced, made us
confident that anti-human Syk antibodies would likely recognize rat Syk with a
comparable degree of affinity.
The results of other optimization procedures are summarized in Figure 9 and will be
further discussed here. An initial parameter tested, prior to acquisition of the CST ELISA
kit, was to optimize the density of cells to be cultured the night before the experiments.
The target confluence of these dishes was to be between 80-90% as recommended by the
manufacturers of the ELISA kit and the densities tested were scaled up from our own
experiments on 96-well microplates. Upon microscope inspection of various replicated
dishes, it was concluded that cells were to be cultured at 11.375x106 cells per dish and
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incubated overnight prior to harvesting for the ELISA experiments. The concentration of
the detergent in our lysis buffers was also evaluated and optimized. Although the kit
included a lysis buffer, we decided to test lower concentrations of the lysis detergent TX100 in an effort to disturb the fragile phosphorylation events that we being targeted. It
was found that the combination of scrapping and a 1% TX concentration found the
manufacturers lysis buffer) of lysis buffer was crucial for proper cell lysis. The
recommendations of the manufacturer were then followed in this regard as they produced
the most substantial lysis of the treated cells.
Optimization of the protocol included within, however, is far from complete. Our
group suspects that the sensitization, stimulation, and exposure steps (the most sensitive
steps of the procedure) are likely to be the source of variability in our data. Our first issue
with the optimization of these steps was the sensitization of our cultured cells. For most
other experiments we are accustomed to using monoclonal anti-DNP IgE antibodies over
the period of one hour immediately after the cells have cultured overnight. These
antibodies are manufactured by Sigma-Aldrich and have had a tendency to cluster during
long incubation times (unpublished observation). As we continue to optimize our
experiments we are worried that these antibodies are not sensitizing cells properly and
thus depriving the full extent of degranulation when they are stimulated. A possible
solution to this issue has been proposed, and is currently in the process of being
implemented. The Baird-Holowka lab (Cornell University, Ithaca, NY, USA) has kindly
donated a stock of in-house produced and purified anti-DNP IgE antibodies that do not
exhibit the aggregation issues of the Sigma IgE. These antibodies will enable for the
sensitization to occur overnight, as it is often recommended when sensitizing RBLs, and
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perhaps maximize the chances of catching a glimpse into the short lived window of
phosphorylation of these vital PTKs.
A second possible source of variability in our data refers to the time and procedure
involving the stimulation of the cells with DNP-BSA. Several publications argued that
Syk phosphorylation was maximal upon 2 min stimulation with antigen and decreased
significantly thereafter [74, 82, 83]. We carried out a pair of ELISA experiments to verify
these finding with stimulation times of 2 min and 5 min but the resulting the data
contradicted itself (data not shown). In the end we concluded we would continue using
the 5 min stimulation as it exhibited the largest percentage increase over spontaneous in
the majority of experiments carried out thereafter. This part of the protocol is of vital
importance and more effort should be taken to optimize the incubation time of
stimulation.
A third possible source of error in our Phospho-Syk ELISA protocol is the lysis
procedure that occurs immediately after stimulation. Upon the crosslinking of the
receptors and the recruitment of the PTKs there is a rapid phosphorylation of these PTKs
that helps in propagation and enhancement of the stimulation signal. Almost immediately
upon the activation of these PTKs, proteases and phosphatases begin dephosphorylating
these PTKs to return them to their original inactivated state (see Introduction for more
details). In an effort to conserve the phosphorylated state of Syk, our lysis buffer contains
many anti-phosphatases and anti-proteases such as sodium orthovanadate (protein
tyrosine phosphatases inhibitor), β-glycerophosphate (serine-threonine phosphatase
inhibitor), leupeptin (inhibitor of serine and cysteine proteases), sodium pyrophosphate
(Ser/Thr phosphatase inhibitor). Along with these vital components in the buffer, it was
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also advised by the manufacturing company that all lysis steps are carried out promptly
and at “ice-cold” conditions as to preserve the phosphorylated proteins. Within this
crucial handling of the lysates we encounter the sonication step of cells scraped off the
bottom of the treatment dishes. This sonication procedure provided many issues in terms
of timing, loss of lysate volume due to splashing or excessive bubbling, and the sample
heating from repetitive sonication. The latter issues were resolved by switching to more
voluminous tubes and maintaining these lysate tubes submerged in a water-ice slurry
during the whole sonication procedure. The issue of the timing, however, remained an
elusive issue that we attempted to address. It was concluded that that sonicating the
lysates at 35 Watts 3 times for 5 seconds with 10 seconds breaks in between resulted in
the fastest sonication procedure that resulted in full cell lysis (Figure 9). These changes,
as well as an acquired expertise with the protocol, have resulted in improved data yields
that allowed us to make preliminary conclusions about the possible mechanism of arsenic
toxicity in mast cell degranulation.
Preliminary data from the ELISA experiments yielded promising results. In the
presence of 750 ppb arsenic, there was an observed decrease in the phosphorylation of
Syk as measured by our ELISA. This experiment included two biological controls per
treatment as well as a third procedural repeat for both antigen stimulated samples and the
spontaneous control samples. It is difficult to make conclusions with much confidence as
these results showed a high variability amongst the samples and was unable to reach
statistical significance at any considerable level. However, as preliminary results they are
promising and could provide some insight into the mechanism of mast cell inhibition by
arsenic. If these results can be replicated, then we could potentially conclude that As is
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inhibiting degranulation by interfering with the phosphorylation of Syk. Possible
mechanisms for this interference could be direct as is the case with the isostructural
competition of arsenate with free-phosphate as discussed in the discussion of the
combined piceatannol-arsenic assays and reported across many model organisms
[13,14,16, 92]. Another direct way in which As could be acting is by interacting with
sulfydryl groups of proteins. A study found that arsenite interacted with sulfhydryl
groups of certain proteins, causing detrimental structural modification or denaturation
[92, 92, 94]. These structural modifications, as reported by Akter et al, can be a vital
source of protein inactivation across many organisms [95]. Since both human and rat Syk
contain numerous cysteine residues, five of which are located specifically in its kinase
domain, inactivation via sulfhydryl interaction is a realistic possibility that should be
considered (Figure 12). Our data from the piceatannol-arsenic combination assays
presented above, as well as the preliminary ELISA results, appear to point towards a
more direct mode of action for arsenic-induced inhibition of degranulation. Since arsenic
was found to have an additive effect with piceatannol and a possible specific interference
in Syk phosphorylation, it is possible that As could be inhibiting Syk by directly blocking
the sites of Syk phosphorylation or by inactivating Syk altogether through structural
modifications caused by sulfhydryl interactions.
There still exists the possibility that arsenic could be acting indirectly to inhibit Syk.
As previously stated, arsenic could also be inhibiting the phosphorylation of Syk
indirectly through the stimulation of oxyradical production [13, 16, 20, 93]. These ROS,
primarily found to be superoxide, hydroxyl radicals and H2O2, have been correlated with
damaging amino acids, purine nucleotides, nucleic acids, and proteins [93]. It is possible
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that arsenic could be stimulating the production of these harmful radicals and thus the
inactivation of not just Syk but many other molecules in the periphery. More experiments
will need to be carried out before a mechanism of arsenic-induced inhibition can be
elucidated.
The implications of these results can help researchers better understand the mode of
arsenic toxicity that is likely to not be organism specific. If arsenic, in fact, does inhibit
Syk in a direct manner, then it is possible that it may be inhibiting other similar
molecules in the same manner. Furthermore, since arsenic has already been shown to
inhibit such a vital pathway in allergy and asthma development, then it is possible for Syk
to be used a drug target to treat these diseases. By pharmacologically mimicking the
effect of arsenic on Syk, in theory, it could be possible to develop a drug to inhibit the
degranulation of mast cells and perhaps alleviate the burden that hypersensitive continues
to have in developed countries.
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